Chronic central serous chorioretinopathy: photodynamic therapy.
OBJECTIVE
To demonstrate, using optical coherence and fluorescien angiography, the efficacy of photodynamic therapy in treating chronic central serous chorioretinopathy.


METHODS
Interventional case series.


METHODS
A retrospective study in a clinical practice setting of four patients (five eyes) with chronic central serous chorioretinopathy. The patients were treated with verteporfin photodynamic therapy and evaluated by optical coherence tomography and fluorescien angiography with average follow-ups of 10 months.


RESULTS
Compared to pre-treatment optical coherence tomography, an acute reduction in subretinal fluid accumulation and serous detachment with stoppage of leakage was noted in the five eyes treated. Dramatic improvement in visual acuity was also noted, especially among patients with better vision initially. However, pigmentary changes persisted.


CONCLUSIONS
Serial optical coherence tomography demonstrates that photodynamic therapy with verteporfin appears to have a beneficial effect in treating patients with chronic central serous chorioretinopathy by reducing fluid leakage, subretinal fluid accumulation, and serous detachment with resultant improvement in vision. Better visual results might be expected if photodynamic therapy is applied earlier in the course of the disease.
Taban
Mehryar
M
Retina-Vitreous Associates, Los Angeles, California, USA.
Boyer
David S
DS
Thomas
Edgar L
EL
Taban
Mehran
M
D000368:Aged; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D002908:Chronic Disease; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin